Hemcheck Sweden AB has signed a 26-month long distribution agreement with Antisel Selidis Bros SA (”ANTISEL”), one of the leading distributors of medical equipment in Greece and Cyprus. The agreement is exclusive regarding the Greek and Cypriotic markets. Antisel has committed to an initial purchase order of readers and one-time tests for a value of 4500 EUR.
– ANTISEL is well established in the local markets to which the agreement applies, and they have shown a lot of interest in Hemcheck and the potential of our products. After the study at Capio, which showed good results, we have started to discuss distribution agreements, initially in countries that approve CE marking but where we currently do not have good opportunity to act on our own. We look forward to working with ANTISEL and hope that it will be a successful and long-term collaboration, says Joen Averstad, CEO of Hemcheck.
– We are very pleased that we have signed an agreement with Hemcheck. Their innovative technology and products fit well into our portfolio and we strongly believe that customers will implement these products in our markets. We very much look forward to the collaboration, says Kostas Gatsos, Commercial Director of ANTISEL.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
ANTISEL is a family-owned Greek company founded in 1967, with offices in Thessaloniki and Athens in Greece, Bucharest in Romania and Sofia in Bulgaria, with a turnover in excess of 30 MEUR. ANTISEL markets and sells medical technology products and provides services such as installation, service, method application and development, data analysis, etc. The company operates in many areas such as Medical Equipment, In Vitro and Molecular Diagnostics, Laboratory and Blood Banking equipment; and is a partner to several large companies such as Thermo Scientific and Instrumentation Laboratory.
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on April 3, 2020 at 18.00